School of Medicine

Wayne State University School of Medicine

CAMPATH I – A yearly infusion or treatment with Rebif® in MS patients who are newly diagnosed- Closed to Enrollment

This is a multi-center study which will examine the safety and compare the efficacy of alemtuzumab (Campath®) to interferon beta-1a (Rebif®) in treatment-naïve patients with Relapsing-Remitting Multiple Sclerosis (RRMS). Patients will be randomly assigned to receive 2 annual cycles of alemtuzumab (12mg/day IV infusion for 5 consecutive days at Month 0 and 12mg daily for 3 consecutive days at Month 12) or 3 weekly subcutaneous Rebif® injections. The study will end 2 years after the last patient has been randomized.

Eligibility: Treatment naïve patients 18-50 yrs old diagnosed with RRMS with an onset of MS symptoms within 5 years of screening. Patients must not have any restrictions with walking and experienced ≥2 MS relapses in the past 24 months, which were confirmed by a physician.

For more information visit: CAMMS323 (CARE-MS I)